Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, Inc. (NASDAQ:RAPP), filed a Form 4 on August 20, 2026, disclosing the sale of 404 shares of common stock on August 19, 2026.
Key Highlights
- Transaction date: 404 shares of Rapport Therapeutics common stock were disposed of on August 19, 2026.
- Sale price: Shares were sold at $49.9 per share, according to the filing.
- Remaining ownership: Following the transaction, the reporting person directly holds 246,022 shares of common stock.
- Rule 10b5-1 plan: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- Reporting person role: Krishnaswamy Yeleswaram is identified as Chief Development Officer of Rapport Therapeutics, Inc.
Rapport Therapeutics CDO Discloses Planned Share Sale Under 10b5-1 Agreement
According to the Form 4 filed with the U.S. Securities and Exchange Commission on August 20, 2026, Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, Inc., reported the disposal of 404 shares of the company's common stock. The transaction was executed on August 19, 2026, at a price of $49.9 per share, with direct ownership recorded as the form of holding.
The filing indicates that the transaction was carried out under a Rule 10b5-1 trading plan, which the reporting person adopted on December 10, 2025. The Form 4 checkbox confirming the Rule 10b5-1(c) affirmative defense conditions is marked. No derivative securities transactions were reported in Table II of the filing.
Following the reported sale, the filing states that Yeleswaram directly beneficially owned 246,022 shares of Rapport Therapeutics common stock. The Form 4 was signed by Troy Ignelzi as Attorney-in-Fact on behalf of the reporting person on August 20, 2026. No amendment to a prior filing was indicated.
What Was Disclosed
The filing disclosed a single open-market sale of 404 shares of Rapport Therapeutics common stock at $49.9 per share by the company's Chief Development Officer on August 19, 2026, executed under a pre-established Rule 10b5-1 trading plan.




Please wait processing your request...